Author

P. Ettmayer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Biochemistry· 1 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:ATAC-seq· 1 Research Focus:benchmarking· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:database / resource· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

A. D. Axtman· 2 shared C. I. Wells· 2 shared D. H. Drewry· 2 shared D. K. Treiber· 2 shared D. M. Andrews· 2 shared H. Al-Ali· 2 shared K. S. Saikatendu· 2 shared M. Frederiksen· 2 shared

Activity by Year

2017-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCell Biology

A. D. Axtman

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Targeting cancer with small molecule pan-KRAS degraders

J. Popow, W. Farnaby, A. Gollner, C. Kofink, G. Fischer, M. Wurm, D. Zollman, A. Wijaya, N. Mischerikow, C. Hasenoehrl, P. Prokofeva, H. Arnhof, S. Arce-Solano, S. Bell, G. Boeck, , A. Ciulli

A single small molecule degrader targets 13 out of 17 prevalent oncogenic KRAS alleles, inhibiting growth of KRAS-driven cancer cell lines and inducing tumour regression in vivo.

bioRxiv · Oct 24, 2023Pharmacology & Toxicology

Nintedanib Targets KIT D816V Neoplastic Cells Derived from Induced Pluripotent Stem cells of Systemic Mastocytosis

M. A. Szymanski de Toledo, M. Gatz, S. Sontag, K. V. Gleixer, G. Eisenwort, K. Feldberg, F. Kluge, R. Guareschi, G. Rossetti, A. S. Sechi, O. Dufva, S. M. Mustjoki, A. Maurer, H. M. Schueler, R. Goetzke, , M. Zenke

This study identifies nintedanib as a novel KIT D816V inhibitor effective against patient-derived neoplastic mast cells in systemic mastocytosis.

bioRxiv · May 6, 2020Cancer Biology

The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification

C. I. Wells, H. Al-Ali, D. M. Andrews, C. R. M. Asquith, A. D. Axtman, M. Chung, I. Dikic, D. Ebner, J. Elkins, P. Ettmayer, C. Fischer, M. Frederiksen, N. S. Gray, S. B. Hatch, S. Knapp, , D. H. Drewry

The paper introduces the Kinase Chemogenomic Set (KCGS), a curated collection of 187 selective kinase inhibitors covering 215 human kinases, for use in cell-based screens.

bioRxiv · Dec 22, 2019Cell Biology

Native mass spectrometry can effectively predict PROTAC efficacy

R. Beveridge, D. Kessler, K. Rumpel, P. Ettmayer, A. Meinhart, T. Clausen

This study shows native mass spectrometry can detect PROTAC-mediated protein interactions and identify preferred E3-PROTAC-POI combinations in competition experiments.

bioRxiv · Nov 25, 2019Biochemistry

Progress Towards a Public Chemogenomic Set for Protein Kinases and a Call for Contributions

D. H. Drewry, C. I. Wells, D. M. Andrews, R. Angell, H. Al-Ali, A. D. Axtman, S. J. Capuzzi, J. M. Elkins, P. Ettmayer, M. Frederiksen, O. Gileadi, N. Gray, A. Hooper, S. Knapp, S. Laufer, , T. M. Willson

The paper shares progress on a kinase chemogenomic set, releases inhibitor profiling data, and calls for community collaboration to complete the set.

bioRxiv · Jan 31, 2017Pharmacology & Toxicology